Talphera Seeks FDA Nod to Close NEPHRO CRRT Trial Early
Talphera has submitted a briefing document to the FDA requesting early closure of its NEPHRO CRRT study after enrollment surpassed 80% statistical power.
Talphera has filed a briefing document with the U.S. Food and Drug Administration requesting a Sprint Meeting to discuss closing enrollment in its pivotal NEPHRO CRRT clinical study, the company disclosed in its third-quarter 2026 financial results and business update.
The company said enrollment figures recorded as of December 31, 2026 form the basis of the request. According to Talphera, the NEPHRO study has already exceeded 80% statistical power for its primary endpoint, a threshold that clinical trial designers typically consider sufficient to detect a meaningful treatment effect and that can support arguments for winding down enrollment ahead of the original schedule.
Read more Huawei Showcases AI Scaling Tools for Global Finance at SFF 2026 →
An early close of enrollment, if granted by the FDA following the Sprint Meeting, could accelerate the company's regulatory timeline for the drug candidate under evaluation in the NEPHRO CRRT program. Sprint Meetings are expedited FDA interactions designed to resolve specific, narrow questions in a compressed timeframe, suggesting Talphera is moving with urgency on this procedural step.
The development represents a potentially significant inflection point for Talphera, as pivotal trial completion is a prerequisite for a New Drug Application submission. Investors and analysts tracking the company will likely watch for the FDA's response to the Sprint Meeting request and any subsequent guidance on the study's final patient count and data readout timeline.
Continue reading at Earnings.